HCV Inhibitor

BO-653 is an orally active anti-atherosclerotic antioxidant that exhibits high binding affinity for LDL. BO-653 scavenges linoleic acid peroxyl radicals, inhibits lipid peroxidation during the auto-oxidation of linoleic acid, and potently suppresses LDL oxidation. BO-653 inhibits Hepatitis C Virus (HCV) replication in a concentration-dependent manner, with an IC₅₀ of 36.0 μM against the HCV subgenomic replicon in FLR3-1 cells. BO-653 demonstrates significant anti-atherosclerotic effects in various animal models, including the Watanabe heritable hyperlipidemic rabbit. BO-653 is suitable for use in research related to atherosclerosis and Hepatitis C Virus infection.

ML279 is a potent scavenger receptor, class B, type I (SR-BI) inhibitor. ML279 can inhibit SR-BI-mediated lipid uptake by stabilizing the binding of HDL to SR-BI (EC₅₀ = 0.27 μM). ML279 can be used for the researches of infection and cardiovascular disease, such as atherosclerosis and HCV infection.

Ciluprevir (BILN 2061; BILN 2061ZW) is an orally active macrocyclic peptide inhibitor of hepatitis C virus (HCV)NS3 protease, with an IC₅₀ of 3 nM. Ciluprevir has Kᵢ values of 0.66 nM and 0.30 nM against genotypes 1b and 1a, respectively. Ciluprevir inhibits HCV RNA replication with an EC₅₀ of 1.2 nM, and its EC50 values against genotypes 1b and 1a are 3 nM and 4 nM, respectively. Ciluprevir shows no significant inhibition against human leukocyte elastase and hepatic cathepsin B. Ciluprevir can be used for genotype 1 HCV infection.

HCV-IN-34 (compound 3i) is an orally active and potent HCV entry inhibitor. HCV-IN-35 shows excellent antiviral activity, with an EC₅₀ of 0.010 μM and a CC₅₀ (half-maximal cytotoxic concentration) of 8.23 μM.

6-Chloro-7-deazapurine-2F-β-D-arabinofuranose is a nucleoside derivative. 6-Chloro-7-deazapurine-2F-β-D-arabinofuranose can be used for synthesis of antiviral agent against hepatitis C virus infection.

Pibrentasvir-d₆ (ABT-530-d₆) is the deuterium labeled Pibrentasvir (HY-101662). Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC₅₀s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.

Daclatasvir-d₁₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively.

ITX 4520 is an orally active and potent hepatitis C virus inhibitor exhibiting an excellent PK profile in both rats and dogs.

MK-4882 is an HCV NS5A inhibitor with activity in reducing viral load in a chimpanzee model of HCV infection, but with issues of viral breakthrough, prompting the development of compounds with greater potency against more genotypes and NS5A resistance mutations.

Radalbuvir (GS-9669) is a non-nucleoside inhibitor of nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase (RdRp). Radalbuvir shows strong anti-HCV potency (GT1a intrinsic EC₅₀ = 2.9 nM, GT1b EC₅₀ = 6 nM).

HCV-IN-38 is a potent, selective and orally active HCV inhibitor (EC₅₀=15 nM, SI=431). HCV-IN-38 has high anti-HCV activity and low cytotoxicity. HCV-IN-38 has a good safety and oral pharmacokinetic profile.

Tetrazolast is a HCV inhibitor with the inhibitory activity ranging from 5% to 20%, extracted from patent WO2005030774.

Ac-DEMEEC-OH is a HCV NS3 protease competitive inhibitor (K_i: 0.6 µM).

MK-0608 (Standard) is the analytical standard of MK-0608 (HY-10244). This product is intended for research and analytical applications. MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC₅₀ of 0.3 μM (EC90=1.3 μM) in the subgenomic-replicon assay.

Rociclovir (HOE 602) is an acyclic nucleoside derivative. Rociclovir protects mice against HSV and MCMV infections, but lacks antiviral activity in cell cultures.

HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor, with an IC₅₀ of 20 μM, a K_d of 29 μM.

Fmoc-leucine-¹⁵N is a ¹⁵N-labeled and ¹⁵N-labled Fmoc-leucine (HY-101064).

Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir sodium salt inhibits SARS-CoV-2 3CL^pro activity.

MK-2748 is a hepatitis C virus (HCV) NS3/4a protease inhibitor. MK-2748 exhibits broad-spectrum and potent antiviral activity, with nanomolar-level activity against all genotypes (gt1a-gt6) (IC₅₀ < 0.115 nM), showing only slightly weaker activity against gt3a (1.212 nM), and maintaining high inhibitory activity against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 can be used in the research of HCV infection.

HCV-IN-45 (Compound EI-1) is an inhibitor for hepatitis C virus (HCV), that inhibits 1a and 1b HCV pseudoparticles with EC₅₀ of 0.134 and 0.027 μM. HCV-IN-45 inhibits 1a/2a and 1b/2a cell culture-adapted HCV (HCVcc), with EC₅₀ of 0.024 and 0.012μM. HCV-IN-45 inhibits the entry of the virus into hepatocyte, and blocks the cell-cell spread.